Compare RXO & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RXO | WVE |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2022 | 2015 |
| Metric | RXO | WVE |
|---|---|---|
| Price | $13.91 | $6.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $16.38 | ★ $31.19 |
| AVG Volume (30 Days) | 1.7M | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,742,000,000.00 | $3,704,000.00 |
| Revenue This Year | $0.78 | $0.34 |
| Revenue Next Year | $6.58 | $83.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 26.20 | ★ 149.43 |
| 52 Week Low | $10.43 | $5.02 |
| 52 Week High | $19.65 | $21.73 |
| Indicator | RXO | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 21.83 |
| Support Level | $12.01 | N/A |
| Resistance Level | $16.62 | $8.15 |
| Average True Range (ATR) | 0.81 | 0.78 |
| MACD | 0.15 | -0.65 |
| Stochastic Oscillator | 68.75 | 14.23 |
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.